Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
Type:
Application
Filed:
July 19, 2017
Publication date:
November 23, 2017
Applicant:
Wyeth LLC
Inventors:
Amanda R. Alley, William A. Bubnis, Stephanie Shield
Abstract: This invention relates to the application of hydroxyapatite chromatography to the purification of at least one antibody from a preparation containing high molecular weight aggregates. Further, this invention relates to an integration of ceramic hydroxyapatite chromatography into a combination chromatographic protocol for the removal of high molecular weight aggregates from an antibody preparation.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
November 21, 2017
Assignee:
Wyeth LLC
Inventors:
Shujun Sun, Christopher Gallo, Brian Kelley
Abstract: Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics.
Type:
Application
Filed:
April 20, 2017
Publication date:
November 9, 2017
Applicant:
Wyeth LLC
Inventors:
Jeffery Jon Seyer, Amy Lee Conder, Angela Pearce Taylor, Bonny Rene Shaw
Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.
Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% glycerin and up to about 10% sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.
Type:
Grant
Filed:
December 12, 2014
Date of Patent:
October 31, 2017
Assignee:
Wyeth LLC
Inventors:
Amanda Alley, William Bubnis, Stephanie Shield
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Type:
Application
Filed:
June 5, 2017
Publication date:
September 21, 2017
Applicant:
Wyeth LLC
Inventors:
Mahdi B. FAWZI, Tianmin ZHU, Syed M. SHAH
Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
Type:
Application
Filed:
May 31, 2017
Publication date:
September 14, 2017
Applicant:
Wyeth LLC
Inventors:
David Hugh Giamalva, Gary Bruce Anderson
Abstract: The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis, and methods related thereto.
Type:
Grant
Filed:
November 11, 2011
Date of Patent:
September 12, 2017
Assignee:
Wyeth LLC
Inventors:
Annaliesa Sybil Anderson, Kathrin Ute Jansen, Mark E. Ruppen, Justin Keith Moran, Susan Kay Hoiseth
Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
September 12, 2017
Assignee:
Wyeth Holdings LLC
Inventors:
Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
Abstract: The invention provides a nutritional supplement and/or pharmaceutical composition for tableting comprising an embedded lubrication matrix. The embedded lubrication matrix comprises an oily liquid finely dispersed in an oil insoluble material. A method of lubricating a nutritional supplement or pharmaceutical composition for tableting using a matrix with embedded lubrication is also provided.
Type:
Application
Filed:
May 22, 2017
Publication date:
September 7, 2017
Applicant:
Wyeth LLC
Inventors:
Yong Dai, Alan M. Goldberg, Michael A. Goode, Raymond Alan Bartolucci, James O. Frazier
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Type:
Grant
Filed:
October 31, 2014
Date of Patent:
August 29, 2017
Assignee:
Wyeth LLC
Inventors:
Mark E. Ruppen, Justin Keith Moran, Kathrin Ute Jansen, Annaliesa Sybil Anderson, Robert G. K. Donald, Narender K. Kalyan, Maninder K. Sidhu, Michael James Flint
Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
Abstract: The present invention provides a compound of formua I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
Type:
Grant
Filed:
September 26, 2016
Date of Patent:
August 8, 2017
Assignee:
Wyeth, LLC
Inventors:
Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Type:
Grant
Filed:
January 29, 2016
Date of Patent:
July 4, 2017
Assignee:
Wyeth LLC
Inventors:
Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
Type:
Grant
Filed:
January 5, 2015
Date of Patent:
June 27, 2017
Assignee:
Wyeth LLC
Inventors:
Stephen Berasi, Robert Vincent Martinez, Michael John Cain, John Martin Wozney, Howard Joel Seeherman, Zong Sean Juo, Valerie Perrine Calabro, Christopher Todd Brown
Abstract: A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
Type:
Grant
Filed:
February 27, 2015
Date of Patent:
June 13, 2017
Assignee:
Wyeth LLC
Inventors:
Yonghui Yuan, Mark Ruppen, Wei-Qiang Sun, Ling Chu, John Simpson, James Patch, Justin Keith Moran, Pamela S. Fink
Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
Type:
Grant
Filed:
July 2, 2014
Date of Patent:
June 6, 2017
Assignee:
Wyeth LLC
Inventors:
George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
Abstract: The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient.
Type:
Grant
Filed:
October 17, 2008
Date of Patent:
May 9, 2017
Assignees:
WYETH LLC, JANSSEN SCIENCES IRELAND UC
Inventors:
Ronald Black, Lars Ekman, Ivan Lieberburg, Michael Grundman, James Callaway, Keith M. Gregg, Jack Steven Jacobsen, Davinder Gill, Lioudmila Tchistiakova, Angela Widom
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
August 22, 2017
Assignee:
Wyeth LLC
Inventors:
Annaliesa Sybil Anderson, Maninder K. Sidhu, Robert G. K. Donald, Kathrin Ute Jansen, Narender Kumar Kalyan, Justin Keith Moran, Mark Edward Ruppen, Michael James Flint